Radiation and immunotherapy: Renewed allies in the war on cancer

OncoImmunology

Volumn 1, Issue 9, 2012, Pages 1645-1647

  Seung, Steven K ^a,b,c   Curti, Brendan ^a,c   Crittenden, Marka ^a,b,c   Urba, Walter ^a,c  

^a EARLE A CHILES RESEARCH INSTITUTE   (United States)

^b Oregon Clinic   (United States)

^c Providence Cancer Center   (United States)

Author keywords

IL 2; Melanoma; Radiation; Renal cell cancer; SBRT

Indexed keywords

B RAF KINASE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DOUBLE STRANDED DNA; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; OX40 LIGAND; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR ANTIGEN;

ADAPTIVE IMMUNITY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DENDRITIC CELL; DOUBLE STRANDED DNA BREAK; DRUG RESPONSE; EFFECTOR CELL; HUMAN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; MELANOMA; MEMORY T LYMPHOCYTE; NONHUMAN; NOTE; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; STEREOTACTIC BODY RADIATION THERAPY; TUMOR ESCAPE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84881661013     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.21746     Document Type: Note

References (10)

1. Prehn RT, Main JM. Immunity to methylcholanthrene- induced sarcomas. J Natl Cancer Inst 1957; 18:769-78
2. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17:2105-16
3. Lange JR, Raubitschek AA, Pockaj BA, Spencer WF, Lotze MT, Topalian SL, et al. A pilot study of the combination of interleukin-2-based immunotherapy and radiation therapy. J Immunother (1991) 1992; 12:265-71
4. Yu P, Rowley DA, Fu YX, Schreiber H. The role of stroma in immune recognition and destruction of well-established solid tumors. Curr Opin Immunol 2006; 18:226-31
5. Ma Y, Aymeric L, Locher C, Kroemer G, Zitvogel L. The dendritic cell-tumor cross-talk in cancer. Curr Opin Immunol 2011; 23:146-52
6. Seung SK, Curti BD, Crittenden M, Walker E, Coffey T, Siebert JC, et al. Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses. Sci Transl Med 2012; 4:137ra74
7. Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 2006; 203:1259-71
8. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 2005; 174:7516-23
9. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23
10. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366:707-14